Jiangsu Yahong Meditech Co Ltd. Stock Analysis 688176.SS

Jiangsu Yahong Meditech Co., Ltd. engages in the research, development, production and commercialization of medicines in the fields of urogenital system tumors and other major disease areas. The company is headquartered in Shanghai, Shanghai and currently employs 497 full-time employees. The company went IPO on 2022-01-07. The firm's product pipeline in women's health, breast cancer, and gynecologic oncology includes APL-1702, APL-2302, and APL-2501. Products in the field of urological oncology include contrast agents that assist in the diagnosis or surgery of bladder cancer, APL-1202/APL-1501, and APL-2401. Products in other disease areas include APL-1401 for ulcerative colitis, APL-2301 for treating infections caused by Acinetobacter baumannii, and APL-1202 for treating Entamoeba histolytica infections.